Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Department of Women's and Children's Health, Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden.
Pediatr Blood Cancer. 2022 Jul;69(7):e29745. doi: 10.1002/pbc.29745. Epub 2022 Apr 30.
Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) implicates enhanced intrathecal chemotherapy, which is related to CNS toxicity. Whether CNS involvement alone contributes to CNS toxicity remains unclear. We studied the occurrence of all CNS toxicities, seizures, and posterior reversible encephalopathy syndrome (PRES) in children with ALL without enhanced intrathecal chemotherapy with CNS involvement (n = 64) or without CNS involvement (n = 256) by flow cytometry. CNS involvement increased the risk for all CNS toxicities, seizures, and PRES in univariate analysis and, after adjusting for induction therapy, for seizures (hazard ratio [HR] = 3.33; 95% confidence interval [CI]: 1.26-8.82; p = 0.016) and PRES (HR = 4.85; 95% CI: 1.71-13.75; p = 0.003).
中枢神经系统(CNS)受累与儿童急性淋巴细胞白血病(ALL)相关,提示需要强化鞘内化疗,而这与 CNS 毒性相关。CNS 受累是否会导致 CNS 毒性尚不清楚。我们通过流式细胞术研究了无强化鞘内化疗、伴有 CNS 受累(n=64)或无 CNS 受累(n=256)的儿童 ALL 患者的所有 CNS 毒性、癫痫发作和后部可逆性脑病综合征(PRES)的发生情况。单因素分析显示,CNS 受累增加了所有 CNS 毒性、癫痫发作和 PRES 的风险,在校正诱导治疗后,CNS 受累增加了癫痫发作(风险比 [HR]=3.33;95%置信区间 [CI]:1.26-8.82;p=0.016)和 PRES(HR=4.85;95%CI:1.71-13.75;p=0.003)的风险。